Trial Profile
Phase II trial of bevacizumab (Avastin) plus pemetrexed (Alimta) and carboplatin in previously untreated advanced non-small cell lung cancer (NSCLC)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 20 Jan 2006 New trial record.